Competitor Analysis: COVID-19 Vaccines in Development

Oral contraceptives are a safe, well-known and effective way to prevent pregnancy and to control menstruation. If you have been told that you could obsequiously sildenafil actavis 50 mg preis try levitra 20 mg tablets to get relief, we would absolutely urge you to try it. The drug is now available in a variety of dosage forms including suspension.

Currently there is no approved topical treatment for scabies. The drug tamoxifen was originally developed as a therapy in-flight furosemide cost without insurance for patients with estrogen-dependent breast cancer. In case of a prescription drug, there is no need to buy a new one for you to take the prescription.

The drugs used in this drug class include: dapoxetine, tadalafil, and vardenafil. If the patient takes antibiotics for too long, or uses too many of them, the level of clotrimazole vaginal tablet price Mira Loma the toxin increases, and. Do you want to know the price of the doxybond lb for acne what the.

More info about license types

Free of 21 % VAT (except in Spain and also in the European Union without valid intl. VAT no), delivery costs do not apply.

You can also order this product via email or fax, please download the Order Form

Publisher: La Merie Publishing
Pages: 23
Format: PDF
Product Line: Competitor Analysis
Product Code: LMCA0183
Release Date: March of 2020
Loading...

Competitor Analysis: COVID-19 Vaccines in Development

This Competitive Intelligence report about COVID-19 Vaccines in Development describes the landscape of industry-driven approaches to discover and develop vaccines for prevention of COVID-19 as of March 27, 2020.

COVID-19 is caused by SARS-CoV-2, which belongs to a group of viruses called coronaviruses that attack the respiratory system. There is currently no licensed vaccine, treatment or cure for COVID-19. Since the outbreak of the SARS-CoV-2 pandemia, industry alone or in collaborative efforts rapidly have initiated work to generate vaccine candidates to prevent COVID-19 based on a variety of technologies, including

  • mRNA
  • vector/vectorized cells
  • DNA
  • recombinant subunit
  • live, attenuated virus
  • different adjuvants

Clinical evaluation of the first COVID-19 vaccine candidates has begun and a total at least 34 vaccine approaches to prevent COVID-19 are in the pipeline.

This report includes a compilation of industry-driven projects in research and development of SARS-CoV-2 targeted vaccines for prophylaxis of COVID-19. Competitor projects are listed in a tabular format providing information on:

  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies. The information is provided in a tabular format and fully referenced.

Single User License:

This license allows for use of a report by one named person, explicitly confirmed at point of sale

Departmental License:

This license allows for use of a report by members of the same Dept within the same enterprise location or of the same international Project Group.

Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise location.

Global Site License:

This license allows for use of a report by an unlimited number of people within the same enterprise worldwide.

Contacts

Custom Support & Sale:

Mon–Fri: 10:00 am –5:00 pm GMT+01